Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andre, Volland"'
Autor:
Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyad Arad Mogadashi, Andre Volland, Bernhard Rupp, Reuben Stewart Harris, Dorothee von Laer
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-12 (2022)
A vesicular stomatitis virus (VSV)-based assay enables high-throughput screening for small molecular protease inhibitors that can block viral proteases, like the Mpro/3CLpro/Nsp5 in SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/ca9da23218ea4e68b17aa315026f2d0f
Autor:
Hye Kyung Lee, Ludwig Knabl, Lisa Pipperger, Andre Volland, Priscilla A. Furth, Keunsoo Kang, Harold E. Smith, Romuald Bellmann, Christina Bernhard, Norbert Kaiser, Hannes Gänzer, Mathias Ströhle, Andreas Walser, Dorothee von Laer, Lothar Hennighausen
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. This prompted investigation of whether or not asymptomatic disease results in measurable immune activation post-infection. Immune activation follo
Externí odkaz:
https://doaj.org/article/210d5784963444e28175c13a1924d367
Autor:
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, Andre Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben S. Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer
Publikováno v:
Science Translational Medicine. 15
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that has been licensed for clinical use. To identify mutations that confer re
Autor:
Emmanuel, Heilmann, Francesco, Costacurta, Seyed Arad, Moghadasi, Chengjin, Ye, Matteo, Pavan, Davide, Bassani, Andre, Volland, Claudia, Ascher, Alexander Kurt Hermann, Weiss, David, Bante, Reuben S, Harris, Stefano, Moro, Bernhard, Rupp, Luis, Martinez-Sobrido, Dorothee, von Laer
Publikováno v:
Science translational medicine.
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor against the SARS-CoV-2 protease 3CL
Protease inhibitors are among the most powerful antiviral drugs. A first protease inhibitor against the SARS-CoV-2 protease 3CLpro, Paxlovid (nirmatrelvir / ritonavir), has recently been authorized by the U.S. FDA for emergency use (EUA 105 Pfizer Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b53353ad8ff2ae2f80938b678b4dcc1
https://doi.org/10.1101/2022.07.02.495455
https://doi.org/10.1101/2022.07.02.495455
Autor:
Hye Kyung Lee, Ludwig Knabl, Lisa Pipperger, Andre Volland, Priscilla Furth, Keunsoo Kang, Harold Smith, Romuald Bellmann, Christina Bernhard, Norbert Kaiser, Hannes Gänzer, Mathias Ströhle, Andreas Walser, Dorothee Von Laer, Lothar Hennighausen
Publikováno v:
Research Square
article-version (status) pre
article-version (number) 1
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
medRxiv
article-version (status) pre
article-version (number) 1
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
medRxiv
SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. This prompted investigation of whether or not asymptomatic disease results in measurable immune activation post-infection. Immune activation following asym